Maria Alfaiate joins Lundbeck as EVP commercial and corporate strategy
Danish CNS specialist Lundbeck (LUND: CO) today announced that Maria Alfaiate has been appointed to the newly-created role of executive vice president, commercial and corporate strategy, and will take up the position on August 1.
Ms Alfaiate will be part of the firm’s executive management team and be responsible for strengthening corporate strategic functions and enhancing global marketing efforts. Her focus will be on optimizing Lundbeck’s ability to capitalize on both present and future opportunities.
Ms Alfaiate Maria joins Lundbeck from Germany’s Bayer (BAYN: DE), where she recently served as senior vice president and global head of new products commercialization and portfolio strategy. Prior to this, she has held positions at AstraZeneca (LSE: AZN) and MSD/ Merck & Co (NYSE: MRK), in global teams but also at country level.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze